Alzheimer's

HHS Xavier Becerra said the 2022 premium should be adjusted downward, but legal and operational hurdles prevented officials from doing that in the middle of the year.

On the Florida Roundup: New research predicts Florida will have one of the fastest growing rates of Alzheimer’s dementia by the middle of this decade.

Medicare has proposed limiting coverage of Aduhelm and several prominent groups representing patients and families are pressing to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.

An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.

Microglia are amoeba-like cells that scour the brain for injuries and invaders. But sometimes the usually helpful cells go into overdrive and damage the brain, researchers say.

Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.

A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.

The condition can be an early signal of Alzheimer’s but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.

Alzheimer's researchers are trying new treatment approaches, including trying to boost the immune system, remove toxic tangles of protein and stimulate brain waves with light and sound.

Some patients who have had COVID-19 develop symptoms resembling early Alzheimer's. Researchers are trying to figure out whether these people are more likely to develop the disease itself.